3 days popular7 days popular1 month popular3 months popular

‘Resistance will be futile’ – Insight into cancer’s evolving defense mechanism

Turning the tables, Katherine Borden at the University of Montreal’s Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek’s Borg in her fight against the disease. “Cancer cells rapidly evolve a multitude of defense mechanisms to evade the effects of the oncologist’s drug arsenal. Unfortunately, clinical strategies to overcome these lag far behind,” Borden explained. “This mismatch likely underlies our inability to implement new durable treatment strategies.” However, in her paper published in Cancer Research entitled “When will resistance be futile?”, Borden describes one way that cancer goes about this evolution, providing researchers with a possible tool for disarming this defense. The article is inspired by research she published in Nature with her doctoral student Hiba Zahreddine.

[Star Trek's Borg Evoked]
Turning the tables, Katherine Borden at the University of Montreal’s Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek’s Borg in her fight against the disease. “Cancer cells rapidly evolve a multitude of defense mechanisms to evade the effects of the oncologist’s drug arsenal. Unfortunately, clinical strategies to overcome these lag far behind,” Borden explained. “This mismatch likely underlies our inability to implement new durable treatment strategies.” However, in her paper published in Cancer Research entitled “When will resistance be futile?”, Borden describes one way that cancer goes about this evolution, providing researchers with a possible tool for disarming this defense. The article is inspired by research she published in Nature with her doctoral student Hiba Zahreddine.

Credit: titan3025

Source

Financing:

This study was supported by National Institutes of Health and Leukemia & Lymphoma Society (LLS) Translational Research Program and Canada Research Chair in Molecular Biology of the Cell Nucleus. Zahreddine holds a Cole Foundation Fellowship and a National Council for Scientific Research Lebanon Fellowship. Katherine Borden also acknowledges support from Pharmascience for this work.

Study cited:

Katherine L. B. Borden published “When Will Resistance Be Futile?” in Cancer Research on December 4, 2014. Borden, Hiba Zahreddine and their colleagues published “The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation” in Nature on May 28, 2014.

University of Montreal